Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+(TM) for Prostate Cancer

Manufacturing Milestone Achieved for Prostate Candidate

By The Northwire Desk — AI Analysis May 14, 2026 · 07:30 BCT · 5.72 BRIACELL THERAPEUTICS CORP. J
Executive Summary
  • Manufacturing Completion: BriaCell completed manufacturing of clinical supplies for Bria-PROS+, its next-generation personalized immunotherapy candidate for prostate cancer.
  • Clinical Plan: The company plans to initiate a Phase 1/2a clinical study for Bria-PROS+ in the coming months.
  • Funding Support: Development is supported by a $2 million non-dilutive grant from the US National Cancer Institute (NCI) awarded in August 2025.
  • Platform Synergy: Bria-PROS+ utilizes the same Bria-OTS+ platform as Bria-BRES+, which recently received FDA IND clearance on May 6, 2026.
  • Preclinical Data: Previous data presented at AACR demonstrated activation of adaptive and innate immunity (naïve T-cells, dendritic cells, NK cells).
  • Contextual Progression: This follows a series of positive updates including Phase 3 enrollment milestones (>230 patients), new clinical site additions (Penn Medicine, NYU Langone), and FDA IND clearance for the breast cancer candidate Bria-BRES+.
Material Impact
  • Incremental Pipeline Expansion: The completion of manufacturing is a necessary operational milestone to advance the prostate program but does not represent a fundamental change in valuation drivers compared to the Phase 3 breast cancer data.
  • Non-Dilutive Capital: The $2 million NCI grant provides specific funding for this indication without equity dilution, which is positive for cash preservation but immaterial relative to total burn rates required for clinical trials.
  • Alignment with Expectations: This news aligns with the previously announced roadmap (NCI grant awarded Aug 2025) and the IND clearance of the breast cancer counterpart in May 2026. It is consistent with historical progress rather than a surprise catalyst.
  • Risk Mitigation vs. Upside: While it reduces execution risk for the prostate program, the primary value driver remains the Phase 3 Bria-IMT study (H1 2026 readout). This news does not materially alter the binary outcome of that pivotal trial.
BCT · Price
Company Overview
  • Company Profile: BriaCell Therapeutics Corp focuses on personalized, off-the-shelf cell-based immunotherapies for cancer.
  • Flagship Project (Breast Cancer): Bria-IMT in combination with an immune checkpoint inhibitor (CPI) is currently in a pivotal Phase 3 study (Bria-ABC). It has FDA Fast Track designation. Primary endpoint is Overall Survival (OS).
  • Secondary Projects:
    • Bria-BRES+ (Breast Cancer): Received IND clearance May 2026, entering Phase 1/2a.
    • Bria-PROS+ (Prostate Cancer): Manufacturing complete, preparing for Phase 1/2a.
  • Platform Technology: Bria-OTS+ platform designed to activate innate and adaptive immunity using genetically engineered whole-cell cancer immunotherapy.
Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other